Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT07090317Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Started Jul 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07090317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090317.